Poor-risk testicular cancer and high-dose chemotherapy

Journal of Clinical Oncology

Volumn 21, Issue 22, 2003, Pages 4073-4074

  Motzer, Robert J ^a   Sheinfeld, Joel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENZOTRIAZOL 1 YLOXYTRIS(DIMETHYLAMINO)PHOSPHONIUM HEXAFLUOROPHOSPHATE; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL; PLATINUM; UNCLASSIFIED DRUG; VINBLASTINE; ICE PROTOCOL 1;

CANCER GROWTH; CANCER RELAPSE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDITORIAL; GERM CELL TUMOR; HUMAN; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; TESTIS CANCER; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; AUTOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MALE; MULTIMODALITY CANCER THERAPY; NOTE; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TESTIS TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; ETOPOSIDE; GERMINOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IFOSFAMIDE; MALE; PROGNOSIS; SURVIVAL RATE; TESTICULAR NEOPLASMS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0642316792     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.08.902     Document Type: Editorial

References (17)

1. Schmoll H-J, Kollmannsberger C, Metzner JT, et al: Long-term results of first-line sequential high-dose VIP-chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: An extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 21:4083-4091, 2003
2. International Germ Cell Cancer Collaborative Group: International germ cell consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15:594-603, 1997
3. Bosl GJ, Motzer RJ: Testicular germ-cell cancer. N Engl J Med 337:242-253, 1997
4. Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435-1440, 1987
5. Hinton S, Catalano PJ, Einhorn LH, et al: Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. Cancer 97:1869-1875, 2003
6. Nichols CR, Williams SD, Loehrer PJ, et al: Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9:1163-1172, 1991
7. Kaye SB, Mead GM, Fossa S, et al: Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: A randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 16:716-724, 1998
8. Motzer RJ, Bosl GJ: High-dose chemotherapy for resistant germ cell tumors: recent advances and future directions. J Natl Cancer Inst 84:1703-1709, 1992
9. McCaffrey JA, Mazumdar M, Bajorin DF, et al: Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: Response and survival. J Clin Oncol 15:2559-2563, 1997
10. Loehrer PJ, Gonin R, Nichols CR, et al: Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16:2500-2504, 1998
11. Bhatia S, Abonour R, Porcu P, et al: High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 18:3346-3351, 2000
12. Rosti G, Pico J-L, Wandt H, et al: High-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumors: First results of a prospective randomised trial of the European Group for Blood and Marrow transplantation-IT-94 study. Proc Am Soc Clin Oncol 21:180a, 2003 (abstr)
13. Donadio AC, Sheinfeld J, Bacik J, et al: Paclitaxel, ifosfamide, and cisplatin (TIP): an effective second-line therapy for patients with relapsed testicular germ cell tumors. Proc Am Soc Clin Oncol 22:383, 2003 (abstr 1537)
14. Harding M, Paul J, Gillis CR, et al: Management of malignant teratoma: does referral to a specialist unit matter? Lancet 341:999-1002, 1993
15. Aass N, Klepp O, Cavallin-Stahl E, et al: Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: A multicenter experience. J Clin Oncol 9:818-826, 1991
16. Norum J, Nordoy T, Wist E: Testicular cancer treated in a minor general oncology department. Eur J Cancer 31A:293-295, 2003
17. Collette L, Sylvester RJ, Stenning SP, et al: Impact of the treating institution on survival of patients with "poor prognosis" metastatic nonseminoma. J Natl Cancer Inst 91:39-46, 2003